HOW CAN ADVERSE EVENTS INFORMATION BE USED TO MORE EFFECTIVELY INFORM CANCER PATIENT CARE?

Due to advances in screening and therapy design, cancer patients are living longer while on or following therapy. Therapy-related adverse events (AEs) are an unintended, but not infrequent, outcome of these treatments. AEs can impact quality of life, adherence to therapy, economic status, and treatment decision-making. This novel qualitative study is the first to undertake a multi-stakeholder evaluation of the impact of AE information on informing cancer patient care in the context of extended survival. The evaluation focuses on a growing subset of cancer patients – those receiving adjuvant therapy. Adjuvant therapies, used to manage many common cancers, lower the risk that the cancer will return. In this setting, mediating the impact of potential acute or delayed adjuvant treatment-related AEs relative to an uncertain potential for tumor recurrence presents important challenges in balancing risks versus benefits. Stakeholder perspectives on generating, disseminating, and/or adjuvant treatment-related AE information were elicited via key informant interviews with patient advocacy, clinical care, regulatory, drug development, and healthcare payer representatives. The stakeholders identified future needs in four key areas: 1) information resources, 2) information integration and implementation, 3) value systems and culture, and 4) alignment and ownership of collective efforts to improve the use of AE information in the adjuvant setting. This study revealed the following novel insights: 1) there is cross-stakeholder agreement that change is needed to improve the use of AE information in the adjuvant setting to improve patient outcome, 2) the directionality of needed changes are similar across stakeholders, although specific priorities varied, and 3) the potential to realize broad systemic progress in the use of adjuvant-related AE information is a challenge that lacks clear ownership. This lack of ownership has adversely impacted resourcing, efficiency, and collective progress and is likely to be a progress-limiting factor in realizing transformational change. To address the system-limiting challenges identified in this research, a proposed approach to incentivize and support stakeholders in forward action is offered. The proposal offers an infrastructure to promote collaborative and independent efforts in fulfillment of the many scientific, economic, communication, social, and implementation challenges identified in this research study.Doctor of Public Healt

Implementing a National Cancer Clinical Trials System for the 21st Century - Second Workshop Summary

http://www.nap.edu/catalog.php?record_id=1836

Leon Leach, MBA, PhD, Oral History Interview, January 9, 2013

Major Topics Covered: Personal and educational background; faith Career track in corporate insurance Changing economic environment of healthcare, late nineties to 2013 MD Anderson as a fiscal institution: history of operations, bringing sophistication to Tools and strategies for economic forecasting, growth, and fiscal stability Fiscal leadership in an academic institution Strategic initiatives: The Proton Therapy Center, sister institutions, satellite centers, capital campaigns The MD Anderson presidents; Ronald DePinho; The Moon Shotshttps://openworks.mdanderson.org/mchv_interviewsessions/1159/thumbnail.jp

Leon Leach, MBA, PhD, Oral History Interview, April 29, 2013

Major Topics Covered: Personal and educational background; faith Career track in corporate insurance Changing economic environment of healthcare, late nineties to 2013\ MD Anderson as a fiscal institution: history of operations, bringing sophistication to Tools and strategies for economic forecasting, growth, and fiscal stability Fiscal leadership in an academic institution Strategic initiatives: The Proton Therapy Center, sister institutions, satellite centers, capital campaigns The MD Anderson presidents; Ronald DePinho; The Moon Shotshttps://openworks.mdanderson.org/mchv_interviewsessions/1160/thumbnail.jp

Leon Leach, MBA, PhD, Oral History Interview, November 27, 2012

Major Topics Covered: Personal and educational background; faith Career track in corporate insurance Changing economic environment of healthcare, late nineties to 2013 MD Anderson as a fiscal institution: history of operations, bringing sophistication to Tools and strategies for economic forecasting, growth, and fiscal stability Fiscal leadership in an academic institution Strategic initiatives: The Proton Therapy Center, sister institutions, satellite centers, capital campaigns The MD Anderson presidents; Ronald DePinho; The Moon Shotshttps://openworks.mdanderson.org/mchv_interviewsessions/1158/thumbnail.jp

Leon Leach, MBA, PhD, Oral History Interview, November 5, 2012

Major Topics Covered: Personal and educational background; faith Career track in corporate insurance Changing economic environment of healthcare, late nineties to 2013 MD Anderson as a fiscal institution: history of operations, bringing sophistication to Tools and strategies for economic forecasting, growth, and fiscal stability Fiscal leadership in an academic institution Strategic initiatives: The Proton Therapy Center, sister institutions, satellite centers, capital campaigns The MD Anderson presidents; Ronald DePinho; The Moon Shotshttps://openworks.mdanderson.org/mchv_interviewsessions/1157/thumbnail.jp

Nat Cancer

The molecular characterization of tumors now informs clinical cancer care for many patients. This advent of molecular oncology has been driven by the expanding number of therapeutic biomarkers that can predict sensitivity to both approved agents and investigational agents. Beyond its role in driving clinical-trial enrollments and guiding therapy in individual patients, large-scale clinical genomics in oncology also represents a rapidly expanding research resource for translational scientific discovery. Here we review the progress, opportunities, and challenges of scientific and translational discovery from prospective clinical genomic screening programs now routinely conducted for patients with cancer.U54 OD020355/OD/NIH HHSUnited States/U54 OD020355/CD/ODCDC CDC HHSUnited States/R01 CA207244/CA/NCI NIH HHSUnited States/P30 CA008748/CA/NCI NIH HHSUnited States/R01 CA245069/CA/NCI NIH HHSUnited States/R01 CA204749/CA/NCI NIH HHSUnited States/2022-04-06T00:00:00Z35122052PMC898517511193vault:4135

The Comprehensive Cancer Center

This open access book provides a valuable resource for hospitals, institutions, and health authorities worldwide in their plans to set up and develop comprehensive cancer care centers. The development and implementation of a comprehensive cancer program allows for a systematic approach to evidence-based strategies of prevention, early detection, diagnosis, treatment, and palliation. Comprehensive cancer programs also provide a nexus for the running of clinical trials and implementation of novel cancer therapies with the overall aim of optimizing comprehensive and holistic care of cancer patients and providing them with the best opportunity to improve quality of life and overall survival. This book's self-contained chapter format aims to reinforce the critical importance of comprehensive cancer care centers while providing a practical guide for the essential components needed to achieve them, such as operational considerations, guidelines for best clinical inpatient and outpatient care, and research and quality management structures. Intended to be wide-ranging and applicable at a global level for both high and low income countries, this book is also instructive for regions with limited resources. The Comprehensive Cancer Center: Development, Integration, and Implementation is an essential resource for oncology physicians including hematologists, medical oncologists, radiation oncologists, surgical oncologists, and oncology nurses as well as hospitals, health departments, university authorities, governments and legislators